Literature DB >> 11290778

An HLA-DRB1-derived peptide associated with protection against rheumatoid arthritis is naturally processed by human APCs.

A Snijders1, D G Elferink, A Geluk, A L van Der Zanden, K Vos, G M Schreuder, F C Breedveld, R R de Vries, E H Zanelli.   

Abstract

Predisposition to rheumatoid arthritis (RA) is thought to be associated with HLA-DR1, -DR4, and -DR10. However, many epidemiological observations are better explained by a model in which the DQ alleles that are linked to these DR alleles, i.e., DQ5, DQ7, and DQ8, predispose to RA, while certain DR alleles have a dominant protective effect. All protective DRB1 alleles, e.g., *0402, *1301, and *1302, encode a unique motif, (70)DERAA(74). The protection may be explained by the presentation of DRB1-derived peptides by DQ to immunoregulatory T cells, because it was demonstrated in various autoimmune disease models that T cell responses to certain self-Ags can be involved in disease suppression. The aim of this study was to analyze whether peptides carrying the DERAA motif are naturally processed by human APC and presented in the context of the RA-predisposing DQ. Using a synthetic peptide carrying the DRB1*0402-derived sequence (65)KDILEDERAAVDTYC(79), we generated DERAA peptide-specific DQ-restricted T cell clones (TCC) from a DQ8 homozygous individual carrying DERAA-negative DR4 alleles. By analyzing the proliferation of these TCC, we demonstrated natural processing and presentation of the DERAA sequence by the APC of all the individuals (n = 12) carrying a DERAA-positive DRB1 allele and either DQ8 or the DQ8-related DQ7. Using a panel of truncated synthetic peptides, we identified the sequence (67)(I)LEDERAAVD(TY)(78) as the minimal determinant for binding to DQ8 and for recognition by the TCC. These findings support a model in which self-MHC-derived peptide can modulate predisposition to autoimmune disease in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11290778     DOI: 10.4049/jimmunol.166.8.4987

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Genetics in rheumatoid arthritis.

Authors:  Tom W J Huizinga
Journal:  Curr Rheumatol Rep       Date:  2002-06       Impact factor: 4.592

2.  Increased activation-induced cell death in peripheral lymphocytes of rheumatoid arthritis patients: the mechanism of action.

Authors:  Xiaolei Tang; David E Yocum; David Dejonghe; Kathryn Nordensson; Douglas F Lake; John Richard
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

3.  Protective effect of noninherited maternal HLA-DR antigens on rheumatoid arthritis development.

Authors:  Anouk L Feitsma; Jane Worthington; Annette H M van der Helm-van Mil; Darren Plant; Wendy Thomson; Jennie Ursum; Dirkjan van Schaardenburg; Irene E van der Horst-Bruinsma; Jon J van Rood; Tom W J Huizinga; René E M Toes; René R P de Vries
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-06       Impact factor: 11.205

4.  Delineating the role of the HLA-DR4 "shared epitope" in susceptibility versus resistance to develop arthritis.

Authors:  Veena Taneja; Marshall Behrens; Eati Basal; Josh Sparks; Marie M Griffiths; Harvinder Luthra; Chella S David
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

5.  DRB1*0402 may influence arthritis by promoting naive CD4+ T-cell differentiation in to regulatory T cells.

Authors:  David Luckey; Marshall Behrens; Michele Smart; Harvinder Luthra; Chella S David; Veena Taneja
Journal:  Eur J Immunol       Date:  2014-10-20       Impact factor: 5.532

6.  Immunogenicity of a rheumatoid arthritis protective sequence when acquired through microchimerism.

Authors:  Sami B Kanaan; Oyku Sensoy; Zhen Yan; Vijayakrishna K Gadi; Michael L Richardson; J Lee Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-09       Impact factor: 11.205

Review 7.  HLA class II and rheumatoid arthritis: the bumpy road of revelation.

Authors:  Arieke S B Kampstra; René E M Toes
Journal:  Immunogenetics       Date:  2017-07-11       Impact factor: 2.846

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.